H. TAKIGUCHI*, A. HIGASHI, T. WATANABE, T. TAKEICHI, T. SHIMAZAKI, T. INABA*
(JAPAN TOBACCO INC., OSAKA, JAPAN)

Stereocontrolled Synthesis of Delgocitinib, a JAK Inhibitor for the Treatment of Atopic Dermatitis

Org. Process Res. Dev. 2021, 25, 342–348, DOI: 10.1021/acs.oprd.1c00031.

Synthesis of Delgocitinib

Significance: Delgocitinib is a Janus kinase inhibitor that has been approved in Japan for the treatment of atopic dermatitis. The FDA has granted Fast Track Designation to delgocitinib cream for the treatment of adult moderate-to-severe chronic hand eczema.

Comment: The route to delgocitinib depicted delivered the API in 39% overall yield in nine steps without recourse to cryogenic conditions or chromatographic purification. This route has been implemented on a 60 kg scale.

SYNFACTS Contributors: Philip Kocienski
Synfacts 2021, 17(05), 0479 Published online: 20.04.2021
DOI: 10.1055/s-0040-1719790; Reg-No.: K02021SF

© 2021, Thieme. All rights reserved.
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Category

Synthesis of Natural Products and Potential Drugs

Key words

delgocitinib

Janus kinase inhibitor

diastereoselective enolate alkylation

spirocyclization

β-lactam ring formation

Synfact
of the
Month

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.